ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
NCT ID: NCT06026332
Last Updated: 2025-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
400 participants
OBSERVATIONAL
2023-09-15
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
NCT00003725
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT02773849
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
NCT00003129
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
NCT00238420
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ADSTILADRIN
ADSTILADRIN
Non-interventional
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ADSTILADRIN
Non-interventional
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed and dated ICF.
* Age 18 years or older at day ICF is signed.
Exclusion Criteria
* Participants who have previously been treated with ADSTILADRIN in the context of a clinical trial
* Participant is pregnant or breastfeeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ferring Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Compliance
Role: STUDY_DIRECTOR
Ferring Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner Health MD Anderson Cancer Center
Gilbert, Arizona, United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
Arkansas Urology, North Little Rock
Little Rock, Arkansas, United States
Urology Associates of Central California
Fresno, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
UF Health Surgical Specialists - Gainesville
Gainesville, Florida, United States
Mayo Clinic
Jacksonville, Florida, United States
Mount Sinai Medical Center
Miami Beach, Florida, United States
Florida Urology Partners
Riverview, Florida, United States
Florida Urology Partners
St. Petersburg, Florida, United States
Florida Urology Partners
Tampa, Florida, United States
Florida Urology Partners
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
Georgia Urology
Atlanta, Georgia, United States
UROLOGY OF INDIANA - GREENWOOD FQ: Urology of Indiana US Uro Partners
Greenwood, Indiana, United States
First Urology Research (Jeffersonville)
Jeffersonville, Indiana, United States
Wichita Urology - Wichita Webb
Wichita, Kansas, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Mayo Clinic - Rochester Minnesota
Rochester, Minnesota, United States
Minnesota Urology
Woodbury, Minnesota, United States
The Urology Center, PC
Omaha, Nebraska, United States
AMP UROLOGY, Syracuse - US Urology Partners
Syracuse, New York, United States
SUNY Upstate Medical University Syracuse
Syracuse, New York, United States
Montefiore Medical Center (Bronx2)
The Bronx, New York, United States
Central OH Urology Group - US Urology Partners
Gahanna, Ohio, United States
Atlantic Urology Clinics - McLeod Health Blvd
Myrtle Beach, South Carolina, United States
Urology Associates P C (Nashville)
Nashville, Tennessee, United States
University of Texas Southwestern Medical Center (Dallas)
Dallas, Texas, United States
University of Utah (Salt Lake City)
Salt Lake City, Utah, United States
University of Virginia Health System
Charlottesville, Virginia, United States
Urology of Virginia (Virginia Beach)
Virginia Beach, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Global Clinical Compliance
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
000431
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.